zimberelimab,etrumadenant,domvanalimab
gilead,otsuka,arcus biosciences
['lung', 'domvana', 'arc-7', 'gilead', ' arcus ']
gilead and arcus present p-ii study (arc-7) results of domvanalimab as 1l treatment of non-small cell lung cancer at asco 2023 #clinicaltrials 
Real-time summarized News in 3 shots from pharma, biotech, medtech, digital health and life sciences industry readable in 60 seconds